Cite
HARVARD Citation
Horňák, T. et al. (2020). Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study. Leukemia & lymphoma. 61 (2), pp. 494-496. [Online].